Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1774Triple Negative Breast Neoplasms 299Ovarian Neoplasms 135Lung Neoplasms 115Colorectal Neoplasms 115Neoplasms 106Prostatic Neoplasms 102Carcinoma, Non-Small-Cell Lung 101Neoplasm Metastasis 96Stomach Neoplasms 81Pancreatic Neoplasms 78Melanoma 74Endometrial Neoplasms 64Head and Neck Neoplasms 60Uterine Cervical Neoplasms 56Squamous Cell Carcinoma of Head and Neck 50Colonic Neoplasms 45Esophageal Neoplasms 42Carcinoma, Intraductal, Noninfiltrating 41Sarcoma 40Motor Activity 37HER2-positive Breast Cancer 34Urinary Bladder Neoplasms 33Liver Neoplasms 31Carcinoma, Renal Cell 30Brain Neoplasms 28Advanced Breast Cancer 25Lymphedema 24Kidney Neoplasms 24Carcinoma, Transitional Cell 23

Interventions

Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Early Hormone Receptor-positive Breast Cancer × Breast × Clear all
NCT04278469 2020-02-20

Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy

Gencurix, Inc.

Phase NA Recruiting
194 enrolled
Breast

Early Hormone Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡